Announcements Trials

Browse Landscape Eligibility

Clinical Trials

2 trials

Recent Start date Enrollment

Terminated × Has announcements × trastuzumab deruxtecan × Clear all

Phase

Status

Completed 4 Active not recruiting 3 Terminated 2 Recruiting 1

Sponsor Class

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1 Breast 1

Conditions

Neoplasm Metastasis 2 Carcinoma, Non-Small-Cell Lung 1 Breast Neoplasms 1

Interventions

TIC10 compound 3 trastuzumab deruxtecan 2 umbralisib 1 ublituximab 1 duvelisib 1 blinatumomab 1 belumosudil 1 Rituximab 1 KD025 1 Crizotinib 1 Bendamustine Hydrochloride 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03248492 2025-06-26

DESTINY-Breast01

Daiichi Sankyo

Phase 2 Terminated

253 enrolled 21 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03505710 2025-05-30

DESTINY-Lung01

Daiichi Sankyo

Phase 2 Terminated

181 enrolled 17 charts 1 FDA

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡